XF-73

XF-73

XF-73 (pronounced: eks-ef-seventy-three) is an experimental antimicrobial drug candidate that is being developed by Destiny Pharma. It is a member of the dicationic porphyrin family and is designed to kill bacteria by disrupting their cell membranes.

Etymology

The term "XF-73" is a proprietary name given by Destiny Pharma. The "XF" stands for "X Factor", which is a term often used to denote something that has a significant but hard-to-define influence on a situation or event. The "73" is a sequential number assigned by the company.

Mechanism of Action

XF-73 works by disrupting the cell membrane of bacteria, causing the cells to leak and ultimately die. This mechanism of action is different from most other antibiotics, which typically inhibit the growth and reproduction of bacteria rather than killing them directly.

Clinical Trials

As of 2021, XF-73 is in Phase II clinical trials for the prevention of post-surgical Staphylococcus aureus infections, including MRSA. Preliminary results have shown that XF-73 is effective at reducing the number of Staphylococcus aureus bacteria in the nose, which is a common site of colonization and infection.

Related Terms

• Antimicrobial resistance
• Cell membrane
• Clinical trial
• Dicationic porphyrin
• MRSA
• Staphylococcus aureus

External links

• Medical encyclopedia article on XF-73
• Wikipedia's article - XF-73

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski